New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How do you counsel patients on the risk of thromboembolic complications with use of immunotherapy in NSCLC?

3 Answers

Mednet Member
Medical Oncology · UC San Diego Moores Cancer Center

Patients with metastatic lung cancer are at increased risk of thromboembolic events with an estimated frequency of 13.9% (Connolly et al., PMID 23026639). Preclinical data show that PD-1/PD-1 pathway blockade may lead to increased levels of pro-inflammatory cytokines and T cell driven progression an...

In VTE patients who require indefinite anticoagulation, what clinical factors or patient characteristics lead you to continue full-dose anticoagulation rather than reducing to low-dose anticoagulation for extended secondary prevention?

1 Answers

Mednet MemberInvited Expert
Hematology · Medical University of South Carolina

In patients who, in my judgment, require long-term anticoagulation, I usually switch from a therapeutic dose to a reduced (prophylactic) dose after at least six months of treatment. I base this practice on randomized trials that included patients with unprovoked VTE, including those with thrombophil...

Are there any alternative, hypofractionated RT courses for patients with DLBCL that can be used during the COVID-19 pandemic?

2 Answers

Mednet MemberInvited Expert
Radiation Oncology · David Geffen School of Medicine at UCLA

ILROG recently came out with guidelines pasted below: Synopsis of ILROG Recommendations for Administering Radiotherapy for Hematological Malignancies During Emergency Conditions of the COVID-19 Pandemic • We are facing an increased demand for RT to substitute or complement systemic therapy deemed i...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What is the optimal antithrombotic management, if at all, in patients with incidentally identified findings of multiple silent embolic appearing cerebral infarcts?

2
3 Answers

Mednet MemberInvited Expert
Neurology · HCA Houston Healthcare

It is important to confirm the pattern is embolic. If unsure, input from a specialized physician (such as vascular neurology or neuro-radiology, if available) can aid in confirming the diagnosis. Various white matter findings may mimic an embolic pattern, and distinguishing between unilateral...

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

1
2 Answers

Mednet MemberInvited Expert
Medical Oncology · University of California Davis Comprehensive Cancer Center

I typically do not give enasidenib with azacitidine upfront for patients with AML with IDH2 mutation and ineligible for intensive induction chemotherapy. Based on the results of the VIALE-A study (DiNardo et al, NEJM 2020), I usually give venetoclax with azacitidine to those patients. In addition to...

How do you manage endocrine therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?

3
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Penn Medicine, University of Pennsylvania Health System

This is a difficult situation given that the literature is contradictory on this topic. Both tamoxifen and a factor V Leiden mutation independently increase risk of thromboembolic events. It is unclear whether, together, they would be additive in conferring risk of thrombosis. Dr. Cuzick wrote a ver...

Besides GI evaluation and testing for celiac, what other testing do you consider with a patient with unexplained Iron deficiency anemia and a negative bleeding history?

1 Answers

Mednet MemberInvited Expert
Hematology · Georgetown University School of Medicine

I assume this question comes after endoscopies are negative. Autoimmune gastritis is 30 times more frequent than celiac disease. So anti-parietal cell antibody should be ordered. >30 likely, >50 usually diagnostic. If still negative, a history of long-duration therapy for reflux will explain iron de...

How would you approach radiation for a cutaneous T-cell lymphoma on the nose?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

"Cutaneous T-cell lymphoma" (CTCL) comprises a number of different lymphoma subtypes that arise within the skin. Mycosis fungoides (MF) is, by far, the most prevalent. Consequently, the terms CTCL and MF are often used interchangeably. The treatment for each of these lymphomas is different. Furtherm...

Does anyone utilize P2Y12 assays to determine if clopidogrel may be ineffective when used for DAPT?

7
7 Answers

Mednet MemberInvited Expert
Neurology · HCA Houston Healthcare

Yes, I use P2Y12 assays in two distinct settings. Medical management: If a patient on clopidogrel mono/dual therapy has disease progression with ICAD or experiences a recurrent ischemic event, I obtain a P2Y12 assay to assess responsiveness. This helps guide the decision to switch to ticagrelor and ...

Would you give adjuvant radiation after complete resection of a small primary cutaneous follicular lymphoma of the scalp?

5
4 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

Not a lot of data, but here goes. First, one has to go back decades in the literature to find series of patients with lymphoma rx'd with surgical resection alone. In general addition of RT improved outcome even when ostensibly resected with neg margins. With today's technology risk of additional RT ...